Answers are grounded in this paper and cite their sources.
This review highlights the role of aldosterone and extracellular volume in obesity-associated kidney disease, providing a mechanistic rationale for mineralocorticoid receptor blockade in this population.
Obesity and obesity-associated kidney injuries have played an important role in the rising prevalence of chronic kidney disease (CKD). The link between obesity and kidney disease begins with obesity's well-known associations with diabetes and hypertension, the two leading etiologies of CKD. However, a growing body of evidence suggests that elevated aldosterone levels and expanded extracellular volume are key components of obesity-induced renal disease via aldosterone's non-epithelial effects on the kidney. Highlighting these blood pressure- and diabetes-independent mechanisms of kidney injury in obesity allows an exploration of whether mineralocorticoid receptor blockade, coupled with weight loss and salt restriction, is an optimal treatment for overweight CKD patients.
No takes yet. Share an insight, caveat, or question.
Bomback et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: